Research progress of microRNA in diagnosis and treatment of prostate cancer
10.12092/j.issn.1009-2501.2022.06.014
- Author:
Hao DING
1
;
Yun ZHENG
1
;
Zhenhua GAO
2
;
Yun ZHENG
3
Author Information
1. Faculty of Information Engineering and Automation, Kunming University of Science and Technology
2. Department of Urology, First Affiliated Hospital of Kunming Medical University
3. Institute of Primate Translational Medicine, Kunming University of Science and Technology
- Publication Type:Journal Article
- Keywords:
biomarkers;
CRPC;
miRNA;
prostate cancer;
regulation mechanism;
treatment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(6):696-708
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer (PCa) is an epithelial malignancy that occurs in the prostate tissue and is the second most common cancer in men after lung cancer, affecting millions of men worldwide. MicroRNA (miRNA) is a non-coding small RNA of length 20-22nt that regulates gene expression post-transcriptionally. miRNAs are involved in the regulation of almost all important biological life processes such as cell cycle progression, cell proliferation, cell apoptosis, and cell migration. Recently, more and more studies have shown that miRNAs are involved in the occurrence of various human tumors including PCa. This review summarizes the current research progress of PCA-related miRNAs, and analyzes the role of malregulated miRNAs in the pathogenesis, diagnosis and treatment of PCa. In addition, the role of miRNA in the diagnosis and treatment of castration-resistant prostate cancer (CRPC) is emphasized.
